Skip to main content

Promus ELITE™

Everolimus-Eluting Platinum Chromium Coronary Stent System

Clinical Outcomes

The Promus ELITE Stent System builds on the proven outcomes of almost 10,000 patients in 11 clinical trials of the PLATINUM family of trials.

Nearly 10,000 Patients in the PLATINUM Family of Trials and Over 8 Million Promus PtCr DES Implanted Worldwide1

PLATINUM Workhorse Trial

Study Objective
Evaluate the safety and effectiveness of the Promus PtCr EES Coronary Stent System* for the treatment of patients with up to 2 de novo lesions ≤ 24 mm in length; ≥ 2.50 mm to ≤ 4.25 mm in diameter compared to the Xience CoCr EES.

Study Design
Prospective, Randomized, Controlled, Non-inferiority, Multicenter

Numerically Lower Ischemia-Driven TLR Through 5 Years2

Numerically Lower Event Rate Through 5 Years2


Outstanding Safety Shown in Real-World Use

Kang Network Meta-Analysis3

Promus PtCr EES ranked #2 for the lowest relative risk of Def/Prob Stent Thrombosis

SCAAR Registry4

Promus PtCr EES reported numerically lowest Permanent Polymer ST Rates in real-world SCAAR Registry
Product Overview

Product Overview

Built to offer outstanding acute performance and proven long-term outcomes.



Enhanced delivery system for the optimal balance of pushability, flexibility and trackability.

Stent Design

Stent Design

Customized stent architecture offers the ideal balance of strength and flexibility.